A renowned leader in neuroscience research, Dr. Robin Carhart-Harris heads the Centre for Psychedelic Research at Imperial College London, where he has designed a number of functional brain imaging studies with psilocybin, LSD, MDMA, and DMT and completed two clinical trials of psilocybin for depression. Dr. Carhart-Harris has over 100 published papers in peer-reviewed scientific journals. Dr. Carhart-Harris’ research has, among many other findings, shown that 67% of patients who underwent psilocybin treatment experienced remission of their ‘treatment-resistant’ depression at 1-week post-treatment.
Dr. Carhart-Harris will provide his scientific expertise to advise Osmind on its strategy to support the discovery, development, commercialization, and delivery of novel mental health therapies, including psychedelic and psychedelic-based therapies. These therapies have presented immense hope to patients who have failed traditional antidepressants, an estimated ⅓ of the depressed patient population.
Osmind has already launched its Electronic Health Record (EHR) to treatment-resistant mental health providers around the country, becoming the #1 EHR for intensive mental health clinics, which use modalities such as ketamine. With Dr. Carhart-Harris’ advisorship, Osmind will further expand its provider network and deepen its ability to help researchers advance these therapies, ultimately building the underlying infrastructure for these therapies to become widely adopted.
“I have been impressed with Osmind’s progress in the ketamine therapy space, filling an important need with regard to digital health recording and data capture,” said Dr. Carhart-Harris. “I am delighted to have this opportunity to contribute to their continued success.”
L. Alison McInnes, MD, MS, Medical Director at Osmind commented, “We are thrilled to welcome Dr. Carhart-Harris to our Scientific Advisory Board. His expertise across psychedelic modalities will be invaluable for us to deepen our software’s utility and ability to aggregate useful insights for researchers, clinicians and patients. Collectively, our team has expertise across technology, psychiatry, neuroscience, and more to advance therapeutics for treatment resistant mental health conditions.”
Osmind enables the discovery, development, commercialization, and delivery of next-gen mental health treatments. It has built the first data engine and digital infrastructure for treatment-resistant mental health, unlocking novel therapeutic approaches and precision psychiatry. The infrastructure is anchored by Osmind's EHR and Engagement + Outcomes Platform, the #1 software suite for intensive mental health practices (such as those providing FDA-approved psychedelic medicine). Backed by General Catalyst and Y Combinator, Osmind’s team consists of healthcare veterans and software experts (e.g. AWS, Verge Genomics, Kaiser Permanente, Stanford Medicine, Stanford Graduate School of Business).